Literature DB >> 26195258

Neuro-oncology: What is the optimal use of bevacizumab in glioblastoma?

Annick Desjardins1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26195258     DOI： 10.1038/nrneurol.2015.127

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  10 in total

1.  Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft.

Authors:  D F Stefanik; W K Fellows; L R Rizkalla; W M Rizkalla; P P Stefanik; A B Deleo; W C Welch
Journal:  J Neurooncol       Date:  2001-11       Impact factor: 4.130

Review 2.  Lessons from phase III clinical trials on anti-VEGF therapy for cancer.

Authors:  Rakesh K Jain; Dan G Duda; Jeffrey W Clark; Jay S Loeffler
Journal:  Nat Clin Pract Oncol       Date:  2006-01

3.  Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.

Authors:  Martin J B Taphoorn; Roger Henriksson; Andrew Bottomley; Timothy Cloughesy; Wolfgang Wick; Warren P Mason; Frank Saran; Ryo Nishikawa; Magalie Hilton; Christina Theodore-Oklota; Arliene Ravelo; Olivier L Chinot
Journal:  J Clin Oncol       Date:  2015-05-26       Impact factor: 44.544

Review 4.  Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme.

Authors:  Bruno Kovic; Feng Xie
Journal:  J Clin Oncol       Date:  2015-05-26       Impact factor: 44.544

5.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

Authors:  Olivier L Chinot; Wolfgang Wick; Warren Mason; Roger Henriksson; Frank Saran; Ryo Nishikawa; Antoine F Carpentier; Khe Hoang-Xuan; Petr Kavan; Dana Cernea; Alba A Brandes; Magalie Hilton; Lauren Abrey; Timothy Cloughesy
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

6.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

7.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.

Authors:  Teri N Kreisl; Lyndon Kim; Kraig Moore; Paul Duic; Cheryl Royce; Irene Stroud; Nancy Garren; Megan Mackey; John A Butman; Kevin Camphausen; John Park; Paul S Albert; Howard A Fine
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

8.  Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes.

Authors:  Sophie Godard; Gad Getz; Mauro Delorenzi; Pierre Farmer; Hiroyuki Kobayashi; Isabelle Desbaillets; Michimasa Nozaki; Annie-Claire Diserens; Marie-France Hamou; Pierre-Yves Dietrich; Luca Regli; Robert C Janzer; Philipp Bucher; Roger Stupp; Nicolas de Tribolet; Eytan Domany; Monika E Hegi
Journal:  Cancer Res       Date:  2003-10-15       Impact factor: 12.701

9.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Authors:  Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

10.  Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.

Authors:  Emil Lou; Katherine B Peters; Ashley L Sumrall; Annick Desjardins; David A Reardon; Eric S Lipp; James E Herndon; April Coan; Leighann Bailey; Scott Turner; Henry S Friedman; James J Vredenburgh
Journal:  Cancer Med       Date:  2013-01-24       Impact factor: 4.452
  10 in total
  5 in total

1.  Extensive epidural extension growth of a glioblastoma: a case report and literature review.

Authors:  Jinlu Yu; Limei Qu; Xu Zheng; Hongfa Yang
Journal:  Int J Clin Exp Med       Date:  2015-11-15

Review 2.  On glioblastoma and the search for a cure: where do we stand?

Authors:  John Bianco; Chiara Bastiancich; Aleksander Jankovski; Anne des Rieux; Véronique Préat; Fabienne Danhier
Journal:  Cell Mol Life Sci       Date:  2017-02-17       Impact factor: 9.261

3.  Glioblastoma stem cell differentiation into endothelial cells evidenced through live-cell imaging.

Authors:  Xin Mei; Yin-Sheng Chen; Fu-Rong Chen; Shao-Yan Xi; Zhong-Ping Chen
Journal:  Neuro Oncol       Date:  2017-08-01       Impact factor: 12.300

Review 4.  Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization.

Authors:  Rong Shao; Sherry L Taylor; Dennis S Oh; Lawrence M Schwartz
Journal:  Oncotarget       Date:  2015-12-01

5.  Chitinase-3-like 1 protein complexes modulate macrophage-mediated immune suppression in glioblastoma.

Authors:  Apeng Chen; Yinan Jiang; Zhengwei Li; Lingxiang Wu; Ulises Santiago; Han Zou; Chunhui Cai; Vaibhav Sharma; Yongchang Guan; Lauren H McCarl; Jie Ma; Yijen L Wu; Joshua Michel; Yi Shi; Liza Konnikova; Nduka M Amankulor; Pascal O Zinn; Gary Kohanbash; Sameer Agnihotri; Songjian Lu; Xinghua Lu; Dandan Sun; George K Gittes; Qianghu Wang; Xiangwei Xiao; Dean Yimlamai; Ian F Pollack; Carlos J Camacho; Baoli Hu
Journal:  J Clin Invest       Date:  2021-08-16       Impact factor: 14.808
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.